Inactive Instrument

Genovis AB (publ.) Share Price Nasdaq Stockholm

Equities

SE0002485979

Medical Equipment, Supplies & Distribution

Financials

Sales 2024 * 155M 14.13M 1.18B Sales 2025 * 238M 21.76M 1.82B Capitalization 1.84B 168M 13.99B
Net income 2024 * 37M 3.38M 282M Net income 2025 * 37M 3.38M 282M EV / Sales 2024 * 11.1 x
Net cash position 2024 * 120M 10.94M 913M Net cash position 2025 * 93M 8.49M 709M EV / Sales 2025 * 7.32 x
P/E ratio 2024 *
48.9 x
P/E ratio 2025 *
21.3 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.42%
More Fundamentals * Assessed data
Dynamic Chart
Carthesian Therapeutics Terminates Genovis AB (Publ.) Licence Agreement CI
Genovis AB (publ.) Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Genovis AB (publ.) Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Genovis to Get $1 Million Milestone Payment for Xork Development MT
Genovis AB (publ.) Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Genovis AB (publ.) Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Genovis Launch Innovative Igm-Specific Protease with Wide-Ranging Applications in Life Science Markets CI
Genovis AB (publ.) Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
ArcticZymes Technologies ASA and Genovis AB Announce Collaboration to Speed Up Penetration and Growth in the Chinese Market CI
Genovis AB (publ.) Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
Genovis AB (publ.) Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Genovis AB (publ.) Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Genovis AB (publ.) Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Genovis Signs Supply Agreement With US Biotech Company; Shares Rise 7% MT
Genovis AB Enters Licensing and Supply Agreement with New Bioprocess Customer CI
More news
Managers TitleAgeSince
Chief Executive Officer 53 01/02/01
Director of Finance/CFO 53 01/22/01
Chief Tech/Sci/R&D Officer 40 01/17/01
Members of the board TitleAgeSince
Chairman 72 05/20/05
Director/Board Member 63 01/19/01
Director/Board Member 75 01/14/01
More insiders
Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The Company markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.
Calendar
More about the company